LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC50s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively[1].
in vivo
LHF-535 (3, 10 or 30 mg/kg; orally; daily; 14 days) protectes mice from a lethal challenge with Tacaribe virus and dramatically reduces viral titers in plasma, spleen, and liver[2]. An increase in survival is also observed when the first dose of LHF-535 (10 mg/kg) is delayed by 1, 2, or 3 days after infection in mice[2].
Animal Model:
IFN-α/β and-γ receptor-deficient AG129 mice[2]
Dosage:
3, 10, or 30 mg/kg/day
Administration:
Orally; daily; 14 days
Result:
Effective as a post-exposure therapeutic.
References
[1] Dongcheng Dai, et al. Antiviral drugs for treatment of arenavirus infection. WO2013123215A2. [2] Madu IG, et al. A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog. 2018 Dec 21;14(12):e1007439. DOI:10.1371/journal.ppat.1007439
